Erasca, Inc. (ERAS) Stock
ERAS has an Alpha Score of 28 out of 100 (poor), computed on Nov 5, 2026 from 2 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported ERAS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $25.08M.
What is ERAS's Alpha Score?
How it works →Alpha Score of 28 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own ERAS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 1.37M | $25.08M | -2% |
| Point72 Steve Cohen | 1.25M | $22.85M | +80% |
| D.E. Shaw David Shaw | 950K | $17.40M | -22% |
| Millennium Management Israel Englander | 910K | $16.67M | +58% |
| Marshall Wace | 757K | $13.87M | +77% |
| Citadel Ken Griffin | 95K | $1.74M | -81% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are ERAS's key statistics?
Key statistics as of Oct 29, 2026
ERAS price chart
Powered by TradingViewWhat does Erasca, Inc. do?
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product candidate is naporafenib, which is currently in pivotal Phase 3 trials (SEACRAFT-2) for patients with NRAS-mutated melanoma. Erasca's pipeline also includes ERAS-0015, a pan-RAS molecular glue designed to treat RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for KRAS-altered solid tumors; and ERAS-12, an investigational EGFR biparatopic antibody for solid tumors. The company employs a modality-agnostic approach to targeting the RAS/MAPK signaling pathway, which is implicated in many human cancers. Erasca maintains a robust cash position to support its clinical development programs and has secured composition of matter patent protection for its key molecules extending through 2043. As a precision oncology specialist, Erasca addresses treatment opportunities in patient populations defined by specific genetic mutations in cancer-driving pathways.